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Abstract
Background: Glycogen synthase kinase-3 (GSK-3) can act as either a tumour promoter or suppressor
by its inactivation depending on the cell type. There are conflicting reports on the roles of GSK-3 iso-
forms and their interaction with Notch1 in pancreatic cancer. It was hypothesized that GSK-3a stabi-
lized Notch1 in pancreatic cancer cells thereby promoting cellular proliferation.
Methods: The pancreatic cancer cell lines MiaPaCa2, PANC-1 and BxPC-3, were treated with
0–20 lM of AR-A014418 (AR), a known GSK-3 inhibitor. Cell viability was determined by the MTT
assay and Live-Cell Imaging. The levels of Notch pathway members (Notch1, HES-1, survivin and cyc-
linD1), phosphorylated GSK-3 isoforms, and apoptotic markers were determined by Western blot.
Immunoprecipitation was performed to identify the binding of GSK-3 specific isoform to Notch1.
Results: AR-A014418 treatment had a significant dose-dependent growth reduction (P < 0.001) in
pancreatic cancer cells compared with the control and the cytotoxic effect is as a result of apoptosis.
Importantly, a reduction in GSK-3 phosphorylation lead to a reduction in Notch pathway members.
Overexpression of active Notch1 in AR-A014418-treated cells resulted in the negation of growth sup-
pression. Immunoprecipitation analysis revealed that GSK-3a binds to Notch1.
Conclusions: This study demonstrates for the first time that the growth suppressive effect of
AR-A014418 on pancreatic cancer cells is mainly mediated by a reduction in phosphorylation of GSK-
3a with concomitant Notch1 reduction. GSK-3a appears to stabilize Notch1 by binding and may repre-
sent a target for therapeutic development. Furthermore, downregulation of GSK-3 and Notch1 may be
a viable strategy for possible chemosensitization of pancreatic cancer cells to standard therapeutics.
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Introduction
The 5-year survival for the patients with pancreatic cancer is
less than 5% owing to the aggressiveness of the disease and the
lack of effective therapies.1–5 It is estimated that the incidence
of pancreatic cancer and mortality will be 48 960 and 40 560,
respectively, in 2015.5 It is projected that by 2030, pancreatic
cancer will likely be the 2nd leading cause of cancer-related
death in the USA.6 Limited treatment options, and success
mandates the development of novel treatment strategies for
pancreatic cancer. Notch1 signalling, a highly conserved path-
way throughout the animal kingdom, plays an important role
in cellular differentiation, proliferation and survival. Both the
Notch1 receptor and its ligands (Delta1 and Jagged1, for exam-
ple) are transmembrane proteins with large extracellular
domains. Binding of the Notch ligand promotes two proteo-
lytic cleavage events in the Notch receptor resulting in the
release of the Notch1 intracellular domain (NICD).7,8 The
released NICD translocates to the nucleus and binds with the
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DNA-binding protein complex CSL [CBF1, Su (H) and LAG-
1], and activates various target genes such as Hairy and enhan-
cer of split (HES)-1, cyclin D1, survivin, etc.7,8 Activated
Notch (NICD) in its free form is unstable and quickly
degraded, which facilitates the regulation of Notch signalling.
Increased expression of Notch receptors and their ligands has
been detected in human pancreatic cancer tissues and cell
lines.9–11 Inhibition of Notch1 or the Notch signalling pathway
by Notch1 siRNA in pancreatic cancer cells enhanced chemo-
sensitivity to gemcitabine.12 Unfortunately, clinical trials utiliz-
ing Notch pathway inhibitors in patients with solid tumours
resulted in significant side effects. However, several clinical tri-
als are underway based on the inhibition of the Notch pathway
via antibody therapy or by gamma-secretase inhibitors (see
review.13,14) Recently, we have reported on xanthohumol, a
natural product from the hop plant, that reduced pancreatic
cancer cell growth predominantly by reduction in Notch1.15
FOLFIRINIX (combinations of 5FU, leucovorin, irinotecan and
oxaliplatin) and gemcitabine (Gem) with nab-paclitaxel treat-
ment on a patient with metastatic pancreatic cancer showed
clinically meaningful improvements.2,16–18 However, acquired
resistance often develops after treatment. One cause of resis-
tance to drug treatment in pancreatic cancer is an increase in
nuclear transcription factor kB (NF-kB) promoter activity by
Notch1.19
Glycogen synthase kinase-3 (GSK-3) is a multifunctional ser-
ine/threonine kinase that exists mainly as a and b isoforms.
GSK-3 plays an important role in diverse biological processes
such as cell-cycle progression, differentiation and apoptosis.20,21
GSK-3 is normally active in cells and predominantly regulated
through the inhibition of its activity by selective phosphoryla-
tion. Briefly, activation of GSK-3a and b is dependent upon
the phosphorylation of residues Tyr279 and Tyr216, respec-
tively. GSK-3 can act as either a tumour promoter or suppres-
sor by its inactivation, depending on the cell type.22 For
example, inactivation of GSK-3 by phosphorylation has been
shown to inhibit the growth of various cancers such as neuro-
blastoma, pancreatic cancer, neuroendocrine cancers and,
therefore, GSK-3 has a potential role in the treatment of can-
cer.23–27 It is not known, however, which isoform of GSK-3
regulates cancer cell proliferation. To date, there are conflicting
and contradictory reports of the role of GSK-3 isoforms in the
modulation of cell growth.28,29 Importantly, most studies con-
ducted on GSK-3 have focused mainly on GSK-3b, and so the
role of the other isoform (GSK-3a) is not clear. Furthermore,
previous studies showed that GSK-3b can phosphorylate NICD
and up-regulate NICD transcriptional activity by controlling
NICD protein stability.30,31
In this study, the specific role of the GSK-3 isoform and the
interaction to Notch1 in pancreatic cancer cells were investi-
gated. AR-A014418 [N-(4-methoxybenzyl)-N0-(5-nitro-1,3-thia-
zol-2-yl)urea], an ATP-competitive and specific GSK-3
inhibitor, treatment reduced pancreatic cancer cellular growth.
Also, the reduction of cellular growth of the pancreatic cancer
cell lines by AR-A014418 was associated with a reduction in
phosphorylation of GSK-3a compared with GSK-3b. Impor-
tantly, treatment resulted in a significant reduction in Notch1
protein suggesting that the phosphorylation of GSK-3a is
required for its stability. A rescue experiment with ectopic
expression of active Notch1 negated the growth suppression
effect of AR-A014418 treatment. Furthermore, knock-down of
the GSK-3 isoform individually indicated that the reduction in
Notch1 is due to depletion of GSK-3a rather than GSK-3b.
Finally, immunoprecipitation analysis suggested that Notch1
binds to GSK-3a.
Materials and methods
Cell lines and culture conditions
The human pancreatic cancer cell lines (AsPC-1, PANC-1,
BxPC-3 and MiaPaCa-2) were purchased from the American
Type Culture Collection (ATCC, Rockville, MD, USA) and
were cultured in Dulbecco’s Modified Eagle Medium (DMEM;
Invitrogen) supplemented with 10% fetal bovine serum (FBS;
Invitrogen) and 1% penicillin/streptomycin (Invitrogen, Grand
Island, NY, USA) at 37 °C in a humidified atmosphere with
5% CO2. Usually, the culture media was replaced every 2–
3 days and the confluent cells were subcultured by splitting




razolium bromide (MTT) and dimethyl sulfoxide (DMSO)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
The AR-A014418 was solubilized in DMSO at stock concentra-
tions of 50 mM and diluted in the media when used for treat-
ment. Antibodies against GSK-3a, GSK-3b, glyceraldehyde
phosphate dehydrogenase (GAPDH), Notch1 and b-catenin,
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and cleaved PARP was purchased from Cell Signal-
ing Technology Inc. (Denvers, MA, USA), active GSK-3a/b
(phosphorylation at 216 and 279) was purchased from Abcam
(Cambridge, MA, USA).
Cellular proliferation
Cells were seeded in 24-well plates and were treated in quadru-
plicates with different concentrations of AR-A014418 for 2 and
4 days as described.15 Cell proliferation/viability was measured
using the colorimetric assay with MTT.24 Values were calcu-
lated to percentage inhibition relative to the vehicle control
(0.1% DMSO).
Non- invasive real-time cellular proliferation assay
Using IncuCyte Live-Cell Imaging systems (Essen Bioscience,
Ann Arbor, MI, USA), the cellular proliferation of the pancre-
atic cancer cell lines was measured as previously described.15
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Briefly, MiaPaCa-2, (1000 cells per well) and AsPC-1 (2000
cells per well) were plated onto a 96-well plate and incubated
in an XL-3 incubation chamber maintained at 37 °C. After
12 h, the cells were treated with varying concentrations of
AR-A014418 (0–50 lM) for up to 4 days. The cells were
photographed every 2 h using a 109 objective for the entire
duration of the incubation. Cell confluence was calculated
using IncuCyte 2011A software and importantly the IncuCyte
Analyzer provides real-time cellular confluence data based on
segmentation of high-definition phase-contrast images. The cell
proliferation was expressed as an increase in the percentage of
confluence in 12-h intervals.
Western blot analysis
Western blot analyses were conducted essentially as
described.24 Cells were lysed in the radioimmunoprecipitation
assay (RIPA; Thermo Fisher, Grand Island, NY, USA) buffer
supplemented with protease inhibitor cocktail (Sigma-Aldrich)
and phenylmethylsulfonylfluoride (Sigma-Aldrich). Equal
amounts of proteins were quantified using the bicinchonic
method (BCA; Thermo Fisher) and analysed by SDS–PAGE
(Bio-Rad Laboratories, Hercules, CA, USA). The proteins were
then transferred to nitrocellulose membranes (Bio-Rad) using
a Trans-Blot (Bio-Rad) and analysed by specific antibodies as
indicated in the experiments. The detection of immune com-
plexes was conducted using chemiluminescence with an HRP
antibody detection kit, and then images were taken using a
Molecular ImagerTM ChemiDoc XRS+ imager with image lab
software (Bio-Rad).
Caspase-3 and -7 activities
The caspase-Glo 3/7 Assay (Promega, Madison, WI, USA) kit
was used to measure the cleaved caspase-3 and -7 activities
from the lysates of cells treated with AR-A014418. Ten to
15 lg of protein samples in 25 lL total volume was mixed
with an equal volume (25 lL) of Caspase-Glo reagent and
incubated at room temperature in a white 96-well plate for
30 min. The luminescence was then measured using an
Infinite M200PRO Microplate reader (TECAN, San Jose, CA,
USA).
Immunoprecipitation
To determine the interaction of GSK-3 isoforms and Notch1









































































































Figure 1 The effect of AR-A014418 on pancreatic cancer cellular proliferation. (a) Colorimetric assay. Human pancreatic cancer cell lines
were treated with AR-A014418 at indicated doses for 2 and 4 days and the cytotoxicity was measured using the MTT assay (n = 3;
P = 0.05 at or above 10 lM concentrations for all cancer cell lines compared with the control. (b) The effects of AR-A014418 on
pancreatic cancer cell proliferation in real-time. Cells were treated with indicated concentrations of AR-A014418 and cell proliferation
was monitored in real time with the continuous presence of the drug. The cells were photographed and the cell confluence was
calculated using IncuCyte 2011A software. The changes in cell confluence are used as a surrogate marker of cell proliferation.
Statistically significant (P < 0.05) growth suppressions were observed at or above 10 lM AR-A014418 compared with the control
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PaCa-2 cell lysates (100 lg) were incubated with GSK-3a,
GSK-3b, Notch1, or a non-specific antibody for 1 h in ice.
Then agarose beads were added and incubated overnight in a
rotator. The next day, lysates were washes three times, and the
final pellet was dissolved in gel loading buffer and analysed by
SDS–PAGE.
Statistical analysis
Analysis of variance (ANOVA) with Bonferroni’s posthoc testing
was performed using a statistical analysis software package
(IBM SPSS Statistics version 22; SPSS Inc., New York, NY,
USA). A P-value of < 0.05 was considered significant. Data
were represented as  the standard error.
Results and Discussion
AR-A014418 treatment reduced pancreatic cancer
cells proliferation
First, we determined the effect of GSK-3 inhibitor, AR-
A014418, on cell viability in four pancreatic cancer cell lines.
PANC-1, MiaPaCa-2, BxPC-3 and AsPC-1 cells were treated
with increasing concentrations of AR (up to 20 lM) for 2 and
4 days and then the cellular viability was measured using the
colorimetric (MTT) assay. Cell viability of pancreatic cancer
cell lines was greatly reduced with increasing concentrations of
AR (Fig. 1a). It had been reported that up to 25 lM concen-
trations of AR did not have any effect on the growth in the
normal human mammary epithelial cell line HMEC and
embryonic lung fibroblast cell line WI38.28 Therefore, the con-
centrations used in these experiments were more effective in
pancreatic cancer cells. To further confirm our result, we have
carried out a real-time non-invasive cellular proliferation assay
using an incucyte analyser. Confluency was significantly
reduced with increasing concentrations of AR in MiaPaCa-2
and AsPC-1 cells tested (Fig. 1b). Our result confirmed the
earlier report on growth suppression of BxPC-3 and Mia-
PaCa-2 cells by AR-A014418 treatment.28
AR-A014418 reduced active GSK-3 phosphorylation
and an associated reduction in Notch1 protein
AR-A014418 treatment has been shown to induce apoptosis
and influences nuclear factor kB (NFkB) in pancreatic cancer
cells.27,28 Recently, we have shown that AR-A014418 treatment
significantly reduced the levels of active phosphorylation of
GSK-3a more than GSK-3b in neuroblastoma.24 In addition,
we showed that treatment reduced the levels of b-catenin in
neuroblastoma.24 Therefore, we wanted to determine whether
the effects of AR-A014418 are similar in pancreatic cancer
cells. To demonstrate this phenomenon, we carried out
Western blots analysis. As seen in Fig. 2a, treatment with
AR-A014418 resulted in a decrease in b-catenin in all three
cell lines tested. This decreased expression is associated with
predominantly decreased phosphorylation of GSK-3a com-
pared to GSK-3b with no change in the total GSK-3 expres-
sion (Fig. 2a). Most importantly, there was a significant
(a)
(b)
Figure 2 Mechanism of action of AR-A014418 in pancreatic cancer cell lines. (a) The levels of b-catenin, active phosphorylated GSK-3,
total GSK-3 and active Notch1 were analysed from lysates after 48 h of AR-A014418 treatment by Western analysis. GAPDH was used
as a loading control. (b) Caspase-3 and -7 activities were measured by the caspase-Glo3/7 assay. (n = 3; P < 0.05 at 10 and 15 lM
treatment compared with the control in all cell lines tested)
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reduction in the level of active Notch1 (Notch1 intracellular
domain, NICD) protein. This is the first report on the effect
of AR-A014418 treatment that reduces the level of active
Notch1 protein. It is interesting because a recent report sug-
gested that GSK-3b plays a key role in the regulation of NFkB
and inactivation of GSK-3b would decrease the cellular prolif-
eration and survival.26–28 Furthermore, in pancreatic cancer
cells, NFkB activity is high and may lead to chemoresistance.
Therefore, inhibition of NFkB activity is favourable to make
pancreatic cancer cells sensitive to chemotherapeutic agents.
Additionally, it has also been reported that there is a cross-talk
between Notch1 and NFkB and downregulation of Notch1 by
curcumin resulting in a reduction in NFkB activity in pancre-
atic cancer cells.32 Recently, we have observed that xanthohu-
mol, a natural product, reduces Notch1 and decreases NFkB
activity in pancreatic cancer cells.15 Ougolkov et al. have
reported that GSK-3 inhibition resulted in reduced NFkB
activity in pancreatic cancer cells.28 We predict that inactiva-
tion of GSK-3 leads to a reduction in Notch1 protein, and this
resulted in reduced NFkB thereby inhibiting cellular prolifera-
tion. As shown in Fig. 2b, the treatment of AR-A014418 in
pancreatic cancer cell lines resulted in increased cleaved cas-
pase-3/7 indicating the induction of apoptosis.
Forced overexpression of active Notch1 reversed the
growth suppression effect of AR-A014418 in
pancreatic cancer cells
Several studies have demonstrated the anti-proliferative
effects of GSK-3 inhibitors including AR-A014418 on variety
of cancer types, but the mechanism of action remains
unclear.23–28,33,34 The observed reduction in cell proliferation
and the associated reduction of the Notch1 protein level suggest
that the Notch pathway inhibition may be important in
AR-A014418 treatment. To examine whether the Notch1
pathway inhibition directly mediates growth suppression by
AR-A014418, active Notch1 (NICD1) was overexpressed in
MiaPaCa-2 cells, treated with AR-A014418 for 2 days, and then
cell viability was measured. Notch1 overexpressed AR-A014418-
treated MiaPaCa-2 cells and showed less growth suppression as
compared with cells transfected with the empty vector (Fig. 3a)
suggesting that inhibition of Notch1 is important for the






















































































Figure 3 Interaction of GSK-3 and Notch1. (a) The effect of Notch1 overexpression in the AR-A014418 treatment. Cells were transfected
with Notch1 plasmid and treated with or without AR-A014418 for 4 days. The percentage of growth was measured by the MTT assay
(n = 3; P = 0.05 at 4 day compared with the vector with AR-A014418 15 lM in MiaPaCa-2 cells tested). (b) Western analysis of the
lysates from the parallel experiment as mentioned in (a), for Notch1 and active GSK-3 proteins. AR-A014418 treatment reduced the level
of active Notch1 expression as well as active GSK-3a phosphorylation in MiaPaca-2 cells (lane 2). However, transfection of active
Notch1 plasmid rescued the phosphorylation of GSK-3a in AR-A014418-treated cells (lane 4). GAPDH was used as a loading control. (c)
Transfection of siRNA against GSK-3a resulted in a reduction in Notch1 level whereas GSK-3b and non-specific, no-target (NS) siRNA
did not alter the levels of Notch1 protein in MiaPaCa-2 cells. GAPDH was used as a loading control. (d) MiaPaCa-2 cell lysates were
immuoprecipitated with Notch1 antibody and then immunoblotted with either GSK-3a or GSK-3b to determine the binding ability to
Notch1 protein. Non-specific antibody did not bind to GSK-3 whereas Notch1 binds to GSK-3a only
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presence of over expressed Notch1 protein (Fig. 3b). As pre-
dicted in the transfected empty vector, AR-A014418-treated
cells showed a reduced expression of both Notch1 and active
GSK-3a phosphorylation. Interestingly, we have observed there
is a slight increase in GSK-3a phosphorylation in Notch1-trans-
fected and AR-A014418-treated cells compared with the trans-
fected empty vector and AR-A014418-treated cells (Fig. 3b lane
2 and 4). The reason for the increase is not known at this time.
However, we speculate that the increase in Notch1 protects
GSK-3a from AR-A014418 treatment by binding.
Interaction of GSK-3a and Notch1 protein
Because AR-A014418 treatment reduced Notch1 protein, and
ectopic expression of Notch1 resulted in the negation of
growth, we next investigated the interaction of Notch1 and
GSK-3. To examine this, MiaPaCa-2 cells were genetically
depleted of either GSK-3a or GSK-3b and the level of active
Notch1 protein was examined. Depletion of GSK-3a lead to a
significant decrease in active Notch1 compared with GSK-3b or
non-specific, no target control transfected cells (Fig. 3c). This
was further confirmed by immunoprecipitation analysis of
GSK-3a or GSK-3b protein (Fig. 3d). As shown, immuoprecipi-
tated with Notch1 antibody lysates detected GSK-3a protein by
immunoblotted whereas GSK-3b did not, indicating that there
is a binding interaction between Notch1 and GSK-3a in pancre-
atic cancer cells. In contrast, earlier studies showed that GSK-3b
can phosphorylate NICD and up-regulate NICD transcriptional
activity by controlling NICD protein stability.30,31 However,
our results identified that GSK-3a is a predominant regulator
of pancreatic cancer cell proliferation and survival through the
inhibition of Notch1 signaling. Furthermore, our results indi-
cated that reduced Notch expression by inactivation of GSK-3
may lead to a reduction in NFkB activity and, therefore,
providing new strategies for pancreatic cancer.
A subcutaneous tumour (pancreatic cancer or colon cancer)
developed in mice treated with AR-A014418 resulted in a sig-
nificant decrease in tumour volume without any adverse effects
on the mice.26,27,35 These data suggested that AR-A014418
would be a novel class of therapeutic agent for cancer. The
present studies indicated that AR-A014418 in combination
with Notch inhibition may be more effective for the treatment
of chemoresistant cancer. Therefore, future studies are war-
ranted to determine the synergistic effect of inhibition of both
GSK-3 and the Notch pathway.
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